Immunoprecise Antibodies Ltd
NASDAQ:HYFT

Watchlist Manager
Immunoprecise Antibodies Ltd Logo
Immunoprecise Antibodies Ltd
NASDAQ:HYFT
Watchlist
Price: 2.26 USD 11.88%
Market Cap: 104.3m USD

Immunoprecise Antibodies Ltd
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Immunoprecise Antibodies Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Immunoprecise Antibodies Ltd
NASDAQ:HYFT
Revenue
CA$20.4m
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Revenue
$43.7B
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
10%
Danaher Corp
NYSE:DHR
Revenue
$24.3B
CAGR 3-Years
-3%
CAGR 5-Years
4%
CAGR 10-Years
5%
Mettler-Toledo International Inc
NYSE:MTD
Revenue
$3.9B
CAGR 3-Years
0%
CAGR 5-Years
6%
CAGR 10-Years
5%
Agilent Technologies Inc
NYSE:A
Revenue
$6.9B
CAGR 3-Years
0%
CAGR 5-Years
5%
CAGR 10-Years
6%
IQVIA Holdings Inc
NYSE:IQV
Revenue
$15.9B
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
11%
No Stocks Found

Immunoprecise Antibodies Ltd
Glance View

ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The company is headquartered in Austin, Texas. The company is advancing Bio-Native AI at the intersection of biology and computation. Its LENSai and HYFT platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. The core of its operations encompasses a diverse suite of proprietary technologies that aid in the exploration, discovery, and development of novel drugs and biologics. Integrated within its wet lab infrastructure is a diverse array of in silico technologies. As an end-to-end service provider of antibody discovery and development, its computational methodologies allow the Company to perform detailed and comprehensive evaluations across various stages of biologic discovery and development. The company is involved in antibody characterization studies, which encompass affinity measurements, epitope landscape profiling, and others.

HYFT Intrinsic Value
1.46 USD
Overvaluation 35%
Intrinsic Value
Price

See Also

What is Immunoprecise Antibodies Ltd's Revenue?
Revenue
20.4m CAD

Based on the financial report for Oct 31, 2025, Immunoprecise Antibodies Ltd's Revenue amounts to 20.4m CAD.

What is Immunoprecise Antibodies Ltd's Revenue growth rate?
Revenue CAGR 5Y
4%

Over the last year, the Revenue growth was -15%. The average annual Revenue growth rates for Immunoprecise Antibodies Ltd have been 1% over the past three years , 4% over the past five years .

Back to Top